Abstract
Anthracyclines, such as doxorubicin (Dox), eradicate tumors by inducing immunogenic cell death (ICD) that both kills tumor cells and facilitates tumor specific immune induction. However, Dox delivered intravenously is associated with systemic toxicity. We have developed dissolvable microneedle arrays (MNAs) that enable direct topical delivery of drugs specifically to the cutaneous tumor microenvironment (TME) without systemic exposure. We hypothesized that application of MNAs delivering Dox to cutaneous tumors, would induce an effective therapeutic antitumor immune response, and that inclusion of a potent TLR3-agonist would improve the tumor specific immune response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
